Management

Douglas A. Hamilton, B.Sc., MBA

President and Chief Executive Officer

Mr. Hamilton was appointed President and Chief Executive Officer of the company on October 1, 2018. Mr. Hamilton has over 25 years’ experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as President, CEO and Director of MetaStat, a precision medicine oncology company. From 2012 to 2014 Mr. Hamilton served as CFO for SEA Medical Systems, a Silicon Valley health-tech company. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox®and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend®and Zithromax®product teams at Pfizer, in addition to the Aranesp®, Epogen®, Stemgen®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.

Ken Sokoll, Ph.D.

Head of Development

Dr. Sokoll has managed several groups in Canada, the U.S. and Europe, including companies such as Aventis-Pasteur (now Sanofi) and United Biomedical Inc. with increasing responsibilities in the fields of pharmaceutical development and regulatory affairs.   He has more than two decades of direct experience in the development of small molecule drugs and biologics specializing in advancing lead clinical candidates through the IND/CTA process and into Phase I and II clinical trials.  Dr. Sokoll received his Ph.D. in Organic Chemistry from the University of Waterloo.

Board of Directors

Parimal Nathwani, MSc, MBA.

Chairman

Mr. Nathwani has over 15 years of experience in various aspects of the biotechnology industry including corporate finance, business development, transactions, intellectual property management, technology development and operations. He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital and in- and out-licensing activities.

Before joining MaRS Innovation, Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly-traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women’s and Children’s Hospital as part of his role at the University of British Columbia’s Industry Liaison Office, and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters.

Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia.  He currently sits on the boards of TRIUMF Innovations, Zucara Therapeutics, Cohesys Inc. and Vasomune Therapeutics and is an observer on the board of Encycle Therapeutics.

Niclas Stiernholm, Ph.D.

Director

Dr. Stiernholm is currently the President and Chief Executive Officer of Trillium Therapeutics Inc. (NASDAQ: TRIL), an immunotherapy research and development company with a strong focus on cancer stem cells. Dr. Stiernholm has served as the President and Chief Executive since the merger in April 2013. Under his direction and leadership, Trillium has raised multiple rounds of venture financing, in-licensed several programs from academic institutions, acquired a private Australian company, and executed significant license agreements with major US biotechnology companies, which generated substantial sublicensing revenues. Dr. Stiernholm joined Trillium from YM BioSciences where he served as Executive Vice President and Chief Scientific Officer. While there, he led the company’s in-licensing efforts and built a broad pipeline of clinical oncology products. Dr. Stiernholm started his career as a member of Allelix Biopharmaceuticals’ business development office. Dr. Stiernholm completed his Ph.D in Immunology at the University ofToronto.

Michael Young

Director

Michael is Executive Vice President and Chief Administrative Officer at Sunnybrook Health Sciences Centre, a major academic health science centre in Toronto, Ontario. With over 30 years of health care experience, Michael has worked in both for-profit and not-for-profit organizations; both in the Canadian and U.S. health care systems. In Ontario, he held past positions as Vice-President, Information and Corporate Services and C.F.O. at Sunnybrook Health Science Centre; Vice-President, Finance and CFO at Markham Stouffville Hospital; Director of Financial Services at the Wellesley Hospital; and Vice-President, Finance at the Riverdale Hospital (now BridgePoint Health). Michael’s private sector and U.S. experience was gained as C.F.O. and Chief Medicare Compliance Officer for the U.S. operation of Dynacare Laboratories (a $300M medical laboratory NASDQ company); Chief Operating Officer of a privately owned diversified holding company; Regional Vice-President for the Canadian operations of Gentiva Health Services (a $1.5B NASDQ home health care company), where he was responsible of full Canadian subsidiary operations; and Managing Director, Bayshore HealthCare (a division of Bayshore Health Group), where he conceived and orchestrated the purchase of and subsequent integration of Bayshore and Gentiva. Michael is a graduate of the University of Toronto. He articled with Ernst and Young, Chartered Accountants and received his CA (now CPA) designation in 1984. He is currently on the boards of CImTeC (Centre for Imaging Technology Commercialization) and CPSR (Canadian Partnership for Stroke Recovery) and is a past Board Member and Chair of the Finance Committee of Markham Stouffville Hospital Foundation and past Chair of Booth Centennial Hospital Linen Services.

In Memoriam:

Dr. Dan Dumont, PhD

Our friend, colleague and co-founder of Vasomune Therapeutics passed away on December 17th, 2015. Dan is remembered as a pioneer in the field of vascular biology; having been the first to discover and describe the importance of Tie2 in blood vessel development and function. Following this pivotal discovery, Dan worked tirelessly to understand the molecular underpinnings of the Tie2 pathway.

Well respected among his peers, Dan’s contributions to the basic understanding of Tie2 signaling were numerous and served to expand scientist’s base of knowledge around how the body responds to vascular injury. Dan’s early work as an investigator, while related primarily to basic research, would later become refocused on translating significant lab discoveries into life-saving medications.

Dan was a senior scientist at Sunnybrook Research Institute and full professor within the Department of Medical Biophysics, University of Toronto. Persevering efforts in the Tie2 space would earn Dan accolades in the form of the Premier’s Excellence Award, William E. Rawls Prize, recognition of excellence from the National Cancer Society Canada and a coveted Tier 1 Canada Research Chair from the federal government.

Dan often spoke of how excited he was to have discovered such an important vascular receptor in his early career and how good fortune would then provide him with the opportunity to develop a drug which could affect a positive outcome for critically ill patients. Dan’s legacy continues with the translation of AV-001 into clinical practice.

Close Menu